Stock listing

Insilico Medicine Cayman Topco

Selected listing: A41XT7 · LS · EUR · DE

Insilico Medicine Cayman Topco (Lang & Schwarz: A41XT7), Health Technology. Latest release Sep 30, 2026: VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE NOMINATES…

A41XT7:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A41XT7
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Lang & Schwarz
Currency: EUR

About Insilico Medicine Cayman Topco

The company focuses on advancing artificial intelligence-driven drug discovery and development. Its innovative approach aims to enhance the efficiency and effectiveness of pharmaceutical research.

Latest news from Insilico Medicine Cayman Topco

VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE NOMINATES NEXT-GENERATION SMALL MOLECULE GIPR ANTAGONIST FOR POTENTIAL INTERVENTION OF OBESITY AND RELATED DISORDERS

September 30, 2026

Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study

September 17, 2026

Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug

September 8, 2026

Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain

September 1, 2026

Commercialization Roadmap Validated with Three-digit Million-dollar Revenue, Insilico Medicine Announces Interim Results for the First Half of 2026

August 27, 2026

All Insilico Medicine Cayman Topco news →

Research Insilico Medicine Cayman Topco

Insilico Medicine Cayman Topco company profile

View the public company page for Insilico Medicine Cayman Topco on 6ix.

Insilico Medicine Cayman Topco news

Read company news and market updates connected to Insilico Medicine Cayman Topco.

Insilico Medicine Cayman Topco investor events

Find investor webinars, events, and replay context for Insilico Medicine Cayman Topco.